Health
The Trial Showed It Was Not Worse. The Label Now Says It Cuts Risk.
The FDA has approved tirzepatide to reduce major cardiovascular events in adults with type 2 diabetes. The trial behind it compared the drug not with placebo but with dulaglutide, an older GLP-1 that already had the indication — and the result was non-inferiority, with an 8 percent lower event rate.
